Testing effectiveness (Phase 2)Ended earlyNCT00699842
What this trial is testing
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Who this might be right for
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8